+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4564662
  • Drug Pipelines
  • 266 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 4

FEATURED COMPANIES

  • AMG 479: Amgen
  • Axitinib: Pfizer
  • CAM2029: Camurus
  • Ibrutinib: Pharmacyclics
  • Pembrolizumab: Merck
  • Ribociclib: Novartis
  • MORE

‘Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors (NETs) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Neuroendocrine Tumors (NETs) - Disease Understanding and Treatment Algorithm

Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor).

The Neuroendocrine Tumors (NETs) market report gives the thorough understanding of the Neuroendocrine Tumors by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors in the US, Europe and Japan.

Neuroendocrine Tumors Epidemiology

The Neuroendocrine Tumors (NETs) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to the publisher, the total number of prevalent cases of Neuroendocrine Tumors (NETs) in 7 MM was found to be 453,191, in the year 2017.

Neuroendocrine Tumors Drug Chapters

This segment of the Neuroendocrine Tumors report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The NETs market forecast provided in the report solely focuses on the market revenue generated by the off-label products (chemotherapy and cytotoxic agents) and targeted therapies that are being used for the treatment of NETs. The somatostatin analogs (SSAs) such octreotide and lanreotide remain the keystone of treatment for most well-differentiated, somatostatin-receptor-expressing metastatic NETs. mTOR inhibitor activity, Angiogenesis inhibitors and Radiolabeled somatostatin analog therapy form the mainstays of NET Therapy. Detailed chapters for upcoming therapies like Azedra (Progenics Pharmaceuticals), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), and Carfilzomib (Amgen) have been covered in the report.

Neuroendocrine Tumors Market Outlook

The Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Neuroendocrine Tumors in 7MM was found to be USD 3.57 Billion in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Neuroendocrine tumors, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan

Neuroendocrine Tumors Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuroendocrine Tumors Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuroendocrine Tumors Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Neuroendocrine Tumors Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Neuroendocrine Tumors market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Tumors market
  • To understand the future market competition in the Neuroendocrine Tumors market.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AMG 479: Amgen
  • Axitinib: Pfizer
  • CAM2029: Camurus
  • Ibrutinib: Pharmacyclics
  • Pembrolizumab: Merck
  • Ribociclib: Novartis
  • MORE
1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance
2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017
2.2. Market (%) Distribution of Neuroendocrine Tumors in 2028

3. Disease Background and Overview: Neuroendocrine Tumors (NET)
3.1. Introduction
3.2. Classification of Neuroendocrine Tumors
3.3. Causes
3.4. Risk Factors
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.7.1. Grading of NETs:
3.7.2. Staging of NETs:

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of NETs
4.3. Total Incident Patient Population of NETs

5. Country Wise-Epidemiology of NETs
5.1. United States
5.1.1. Total Prevalent Cases of NETs in the United States
5.1.2. Total Incident Cases of NETs in the United States
5.1.3. Diagnosed prevalent cases of NETs in the United States
5.1.4. Symptom based classification of NETs
5.1.5. Diagnosed prevalent cases based on Malignancy
5.1.6. Site-specific prevalent cases of NETs
5.1.7. Grade-wise prevalent cases of NETs
5.1.8. Stage-wise prevalent cases of NETs
5.2. EU5 Countries
5.3. Germany
5.3.1. Total Prevalent Cases of NETs in Germany
5.3.2. Total Incident Cases of NETs in Germany
5.3.3. Diagnosed prevalent cases of NETs in Germany
5.3.4. Symptom based classification of NETs
5.3.5. Diagnosed prevalent cases based on Malignancy
5.3.6. Site-specific prevalent cases of NETs
5.3.7. Grade-wise prevalent cases of NETs
5.3.8. Stage-wise prevalent cases of NETs
5.4. France
5.4.1. Total Prevalent Cases of NETs in France
5.4.2. Total Incident Cases of NETs in France
5.4.3. Diagnosed prevalent cases of NETs in France
5.4.4. Symptom based classification of NETs
5.4.5. Diagnosed prevalent cases based on Malignancy
5.4.6. Site-specific prevalent cases of NETs
5.4.7. Grade-wise prevalent cases of NETs
5.4.8. Stage-wise prevalent cases of NETs
5.5. Italy
5.5.1. Total Prevalent Cases of NETs in Italy
5.5.2. Total Incident Cases of NETs in Italy
5.5.3. Diagnosed prevalent cases of NETs in Italy
5.5.4. Symptom based classification of NETs
5.5.5. Diagnosed prevalent cases based on Malignancy
5.5.6. Site-specific prevalent cases of NETs
5.5.7. Grade-wise prevalent cases of NETs
5.5.8. Stage-wise prevalent cases of NETs
5.6. Spain
5.6.1. Total Prevalent Cases of NETs in Spain
5.6.2. Total Incident Cases of NETs in Spain
5.6.3. Diagnosed prevalent cases of NETs in Spain
5.6.4. Symptom based classification of NETs
5.6.5. Diagnosed prevalent cases based on Malignancy
5.6.6. Site-specific prevalent cases of NETs
5.6.7. Grade-wise prevalent cases of NETs
5.6.8. Stage-wise prevalent cases of NETs
5.7. United Kingdom
5.7.1. Total Prevalent Cases of NETs in the UK
5.7.2. Total Incident Cases of NETs in the UK
5.7.3. Diagnosed prevalent cases of NETs in the UK
5.7.4. Symptom based classification of NETs
5.7.5. Diagnosed prevalent cases based on Malignancy
5.7.6. Site-specific prevalent cases of NETs
5.7.7. Grade-wise prevalent cases of NETs
5.7.8. Stage-wise prevalent cases of NETs
5.8. Japan
5.8.1. Total Prevalent Cases of NETs in Japan
5.8.2. Total Incident Cases of NETs in Japan
5.8.3. Diagnosed prevalent cases of NETs in Japan
5.8.4. Symptom based classification of NETs
5.8.5. Diagnosed prevalent cases based on Malignancy
5.8.6. Site-specific prevalent cases of NETs
5.8.7. Grade-wise prevalent cases of NETs
5.9. Stage-wise prevalent cases of NETs

6. Treatment Algorithm

7. Unmet needs

8. Marketed Products
8.1. Afinitor (Everolimus): Novartis
8.1.1. Product Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Other development activities
8.1.5. Safety and Efficacy
8.1.6. Advantages and Disadvantages
8.1.7. Product Profile
8.2. Sutent (Sunitinib Malate): Pfizer
8.2.1. Product Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Other development activities
8.2.5. Safety and Efficacy
8.2.6. Advantages and Disadvantages
8.2.7. Product Profile
To be continued in the report….

9. Emerging Drugs
9.1. Key Cross Competition
9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
9.2.1. Product Description
9.2.2. Product Profile
9.2.3. Product Development Activities
9.2.4. Clinical development
9.2.5. Safety and Efficacy
9.3. AMG 479: Amgen
9.3.1. Product Description
9.3.2. Product Profile
9.3.3. Product Development Activities
9.3.4. Clinical Development
9.3.5. Safety and Efficacy
9.3.6. Advantages and Disadvantages
9.4. Anlotinib: Advenchen Laboratories
9.4.1. Product Description
9.4.2. Product Profile
9.4.3. Product Development Activities
9.4.4. Clinical Development
To be continued in the report….

10. Neuroendocrine Tumors: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Neuroendocrine Tumors (NETs) in 7MM

11. Market Outlook by Country

12. The United States: Market Outlook
12.1. United States Market Size
12.1.1. Total Market size of NETs
12.1.2. Market Size by Therapies

13. EU-5 Countries: Market Outlook
13.1. Germany
13.1.1. Total Market size of NETs
13.1.2. Market Size by Therapies
13.2. France
13.2.1. Total Market size of NETs
13.2.2. Market Size by Therapies
13.3. Italy
13.3.1. Total Market size of NETs
13.3.2. Market Size by Therapies
13.4. Spain
13.4.1. Total Market size of NETs
13.4.2. Market Size by Therapies
13.5. United Kingdom
13.5.1. Total Market size of NETs
13.5.2. Market Size by Therapies
13.6. Japan: Market Outlook
13.6.1. Total Market size of NETs
13.6.2. Market Size by Therapies

14. Market Drivers

15. Market Barriers

16. Appendix
16.1. Report Methodology

17. Publisher Capabilities

18. Disclaimer

19. About the Publisher
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
  • AMG 479: Amgen
  • Anlotinib: Advenchen Laboratories
  • Carfilzomib: Amgen
  • ATG-008: Antengene
  • Ipilimumab: Bristol-Myers Squibb
  • Ribociclib: Novartis
  • Pembrolizumab: Merck
  • RRx-001: EpicentRx
  • Axitinib: Pfizer
  • Cabozantinib: Exelixis
  • CAM2029: Camurus
  • Atezolizumab and Bevacizumab: Genentech
  • Lenvatinib: Eisai
  • Pasireotide LAR: Novartis
  • Spartalizumab: Novartis
  • Tirapazamine: Teclison
  • PEN221: Tarveda Therapeutics
  • Sulfatinib: Hutchison China MediTech
  • Ibrutinib: Pharmacyclics
  • Ramucirumab: Eli Lilly
  • ALT 803: Altor Biosciences
  • Talimogene laherparepvec: Amgen
  • Netazepide: Trio Medicines
Note: Product cover images may vary from those shown
Adroll
adroll